



Universiteit
Leiden
The Netherlands

Role of gut-liver axis in circadian exercise and dietary interventions to improve metabolic health

Kovynev, A.S.

Citation

Kovynev, A. S. (2025, November 6). *Role of gut-liver axis in circadian exercise and dietary interventions to improve metabolic health*. Retrieved from <https://hdl.handle.net/1887/4282356>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4282356>

Note: To cite this publication please use the final published version (if applicable).

Chapter 1

General introduction and thesis outline

General introduction

While the world has successfully managed to tackle the COVID-19 pandemic, it is facing another dangerous, widespread, and costly healthcare challenge, the pandemic of obesity¹. According to the World Health Organization, one in eight people were obese in 2022, and 43% of all adults were overweight; an increasing trend from previous years². Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD)³, is a condition that is characterized by an accumulation of lipids in the liver⁴. This disease, affecting more than 30% of the population, may slowly progress into liver fibrosis and later cirrhosis⁵. Yet, there is only one conditionally-approved pharmaceutical treatment option⁶, with the first-line treatment being lifestyle interventions aimed at weight loss. A loss of 10% of body weight results in clinical improvement of steatosis⁷.

Achieving weight loss is not easy. Any social media feed is full of a plethora of videos and articles with contradictory weight loss advice: “aerobic exercise is best”, “never exercise in the evening”, “only do resistance training”, “exercise does not matter, it is only what you eat” and many more. Asking a clinician for advice is also challenging, as the current clinical guidelines are broad and recommend increased fiber intake and regular exercise training⁸. However it is not known, for instance, what timing or type of exercise training is best, which fiber sources to use or what is the best way of integrating fiber in the diet⁸. Fine-tuning this advice is crucial for the future of combating obesity and MASLD.

Even in the scenario where a patient manages to lose weight and thereby manages to successfully resolve hepatic steatosis, more challenges likely follow. Unfortunately, within a year, an average patient would regain 50% of the lost weight back, with some cases resulting in a higher weight regain than the actual weight loss^{9,10}. The reasons for this are complex and multifaceted. The problem of lifestyle interventions and anti-obesity drug treatment is that they are considered exactly that, an intervention or treatment that would eventually stop^{9,10}. However, if one does not change their lifestyle permanently by adapting food and exercise habits, relapse is likely. Hence, it is imperative to develop interventions that are sustainable in the long term. While body fat loss may be achieved rather quickly, it takes a much longer time for certain biological processes to reach homeostasis and adapt to a new, leaner norm. Some of the processes, like the epigenetic memory of the

adipose tissue, the number of adipocytes in white adipose tissue or leptin dysregulation¹¹⁻¹³, are outside of the scope of this thesis.

An important factor that plays a role in the pathogenesis of metabolic disorders is the gut microbiota^{14,15}. Diet is one of the crucial factors shaping the gut microbiota, and unhealthy diet leads to unfavorable microbiota changes and increased inflammation¹⁶. This, in turn, results in more harmful metabolites being produced and absorbed by the gut (see next section for details), entering the liver via the portal vein. This may result in chronic inflammation and progression of the disease. Shockingly, transplanting the gut microbiota of an obese adult to healthy mice on a chow diet leads these mice to develop obesity, supporting the causal relationships between gut dysbiosis and obesity¹⁷. Hence, developing interventions that positively impact the gut microbiota are likely important for long-term metabolic health¹⁸.

Further in this introduction, I will go more deeply into the outlined topics, defining MASLD and its pathogenesis, the gut-liver axis, and will also go over the existing research about the various lifestyle interventions, such as exercise training and diet modifications.

MASLD pathogenesis

The field of fatty liver disease research went through many changes of defining the disease and its diagnosis in the recent years. Three years ago, it was known as NAFLD. For a brief period, it was known as metabolic dysfunction-associated fatty liver disease (MAFLD), while now the commonly used name is MASLD. This rapid change in definitions underlines the progress that the field has achieved in the last decade to understand the disease's pathogenesis. In the last century, ethanol was considered to be the main contributor to liver dysfunction, so for an average hepatologist the only cause of the liver steatosis would be alcohol intake¹⁹. In 1986, the term NAFLD was introduced, to highlight that liver steatosis can happen without alcohol intake²⁰. However, the name itself does not clarify what the underlying causes are, as it only described that the disease was not related to alcohol intake, but did not refer to the actual cause³. Similarly, in clinical practice it was diagnosed as steatosis that was not caused by alcohol or other identifiable causes, such as hepatitis. Correspondingly, the main theory of NAFLD development was a "two-hit hypothesis"²¹, with the first hit being the development of hepatic steatosis, an accumulation of lipid droplets in hepatocytes leading to lipotoxicity²¹. The second

hit was considered an inflammatory response to stressed hepatocytes, resulting in an influx of immune cells and progressing fibrosis²². To address the problems with naming conventions and diagnosis, the disease definition was briefly changed to MAFLD²³, highlighting the cause being a metabolic dysfunction. This shifted the disease determination to steatosis in the liver and a presence of any metabolic dysfunction, such as obesity, type 2 diabetes (T2D), or other evidence of metabolic dysregulation. The name was promptly changed once again to MASLD to clarify that it is specifically liver steatosis that is the underlying problem, and also to get rid of “fatty”, a stigmatizing word²⁴. Notably, the new guidelines do not exclude the use of alcohol when reaching the disease diagnosis, provided that alcohol consumption is not the underlying cause.

Now that we have defined the main features of the disease and its diagnostics, let us have a closer look at its development (Figure 1). The disease development begins with a lack of physical activity and a caloric intake that is approximately 10% higher, or more, than the recommended amount for an individual^{3,25}. Current research hypothesizes that this leads to a higher lipid accumulation in white adipose tissue and, over time, deteriorating insulin sensitivity of that tissue. With a lack of insulin-mediated lipolysis inhibition in white adipose tissue, more free fatty acids are released in the blood stream, and are then taken up by hepatocytes within the liver²⁶. Simultaneously, increased calorie intake results in increased *de novo* lipogenesis in the liver itself. Together, these lead to an increased accumulation of triglycerides in the hepatocytes. This accumulation, in turn, leads to excessive utilization of the lipids via β -oxidation, causing lipotoxicity^{26,27}. Lipotoxicity is manifested in a number of ways. Toxic intermediate components of lipid metabolism, such as saturated free fatty acids (FFAs), lysophosphatidyl choline or ceramides accumulate in mitochondria, damaging them²⁷. Meanwhile, excessive β -oxidation leads to an increased formation of reactive oxidative species (ROS), damaging mitochondria and other hepatocytes' organelles²⁸. The mitochondrial damage results in mitochondrial dysfunction and, despite sufficient energy availability, impaired ATP production²⁶. Accumulation of toxic lipid metabolites in cytoplasm and ROS from mitochondria lead to endoplasmic reticulum stress and incorrect protein folding, furthering the damage^{26,28}.




Figure 1. Mechanisms of MASLD development. Adapted from Li et al (2024)²⁶. Please see text for the explanation. Red arrows indicate possible negative impact on metabolic health, while black arrows show causality. Abbreviations: ER, endoplasmic reticulum; FFA, free fatty acids; LPS, lipopolysaccharides; SCFA, short-chain fatty acid; TG, triglyceride.

These mechanisms lead to the hepatocytes' stress and damage, causing them to release pro-inflammatory cytokines, such as TNF α , IL-1 β and IL-6. Consequently, Kupffer cells (i.e., resident liver macrophages) are activated, and more monocytes enter the liver from the blood stream^{4,5}. This inflamed state leads to the activation of hepatic stellate cells and their transformation into myofibroblast-like cells, producing extracellular matrix components, such as collagen²⁹. Together, hepatic inflammation and collagen production lead to the development of metabolic dysfunction-associated steatohepatitis (MASH) with pronounced fibrosis^{4,5}. If not addressed, this fibrosis may later progress to cirrhosis, hepatocellular carcinoma, and, in rare cases, liver failure^{4,5}.

However, while lipid accumulation in hepatocytes is the main cause of liver damage, it is not the only one. Bile acid imbalance³⁰, lipopolysaccharides (LPS)³¹, ethanol³² and a lack of short-chain fatty acid (SCFA) influx^{33,34} all contribute and are regulated by gut-liver axis, with an unhealthy gut having a large contribution to MASLD beyond altered calorie uptake.

Gut-liver axis and its role in MASLD development

Gut microbiota stability is instrumental for the maintenance of health. A healthy gut helps maintaining a strong gut epithelial lining, preventing pathogens and LPS from entering the circulation^{14,18,35}. It also protects against pathogens themselves via colonization resistance and supplies the body with high levels of SCFAs^{14,18,35}. The SCFAs are mainly acetate, propionate and butyrate, fermented from dietary fiber, which promote beneficial cardiometabolic health outcomes^{14,18,35,36}.

However, the recent western dietary trends, with increased portion size, calorie-dense snacks and processed foods, rich in (trans-)fats and low in fiber, may lead to a drastic remodeling of the gut microbial community¹⁴. While the gut microbiota composition of most healthy individuals can be classified into one of three enterotypes, patients with obesity/MASLD diffuse into an intermediate state of unfavorable gut microbial composition, with a lack of stable beneficial bacteria³⁷. Correspondingly, this diseased state has recently emerged as one of the most crucial contributors to MASLD¹⁴ (Figure 2). This state is characterized by low α -diversity (the amount of different bacterial species in a sample)¹⁶, with less bacteria being able to produce required metabolites and protect against opportunistic pathogens. With ~70-80% of the immune system already allocated to the gut, this increases the burden on the immune system further³⁸. Additionally, lack of fiber in the diet reduces the abundance of many bacterial producers of SCFAs, especially butyrate¹⁴. Since butyrate functions as the main energy source for enterocytes³⁹, reduction of butyrate in the gut worsens the function of the gut epithelial lining³⁶, resulting in the tight junctions becoming “leaky” and allowing the passing of more particles into the circulation³⁶. A high-fat diet also increases the abundance of bacteria producing inflammatory LPS⁴⁰. Consequently, with increased LPS production and leakage of the gut, more LPS ends up in portal vein and the liver, leading to an increase in inflammation via its recognition by the immune cells and subsequent immune system response⁴¹. Red processed meat is another potential contributor to a worsened gut health. Red meat is rich in sulfur-containing compounds, choline and

carnitine. Upon reaching the gut, they are converted into H_2S , trimethylamine and trimethylamine N-oxide respectively. These compounds damage the epithelial lining and worsen inflammation further⁴². Change in bile acid composition is another gut-mediated factor that may contribute to MASLD. Bile acid metabolism is outside of the scope of this thesis, but the contribution of bile acids to the disease is excellently discussed by Arab et al (2017)⁴³ and expanded on by Lai et al (2023)⁴⁴.




Figure 2. Influence of lifestyle on gut-produced metabolites. Adapted from Song et al (2020)⁴². Please see text for the explanation. Red arrows indicate possible negative impact on metabolic health, green arrows indicate possible positive effect, while black arrows show causality. Abbreviations LPS, lipopolysaccharides; SCFA, short chain fatty acid; TMA, trimethylamine; TMAO, trimethylamine N-oxide;

Surprisingly, another peculiar contributor to MASLD via the gut-liver axis, without alcohol intake, is ethanol. Humans may produce large amounts of ethanol in a rare condition, known as the auto-brewery syndrome, which even makes them intoxicated⁴⁵. However, gut ethanol production was not explored beyond this

condition until recently. Recent findings show that, while the original name of MASLD contained “non-alcoholic”, ethanol is produced in clinically relevant quantities in the gut of MASLD patients, and the elimination of a MASLD-associated microbiota with antibiotics also eliminates bacterial ethanol production^{32,46}.

Taken together, developing treatment strategies for MASLD that improve gut health in addition to steatosis resolution are crucial for successful long-term disease treatment.

Exercise training as MASLD treatment

Physical activity is considered one of the best preventive and curative treatments of cardiometabolic diseases⁴⁷. While sedentary behavior is a massive risk factor, an increase in physical activity correlates with better clinical outcomes⁴⁸. Physical activity refers to any non-sedentary behavior, while exercise training is a planned, more intense and repetitive activity.

Exercise training has long been recommended as an MASLD treatment⁴⁷. Exercise training is an effective tool for weight loss^{49,50} and, as mentioned above, a 10% body weight reduction leads to improved clinical symptoms, such as a reduction in hepatic steatosis and circulating alanine transaminase (ALT) levels, another marker of liver dysfunction. However, weight loss is not the only benefit of exercise training, as exercise reduces liver lipid levels even without an overall body weight change after a 12 weeks intervention⁵¹. Here, a distinction has to be made between different modes of exercise training. First, all programs that were successful in reducing body weight had at least 3 days of exercise training per week, and, second, there is a difference between aerobic exercise training and resistance training⁵². All aerobic protocols, but only 85% of resistance training protocols, were effective in reducing body weight. Notably, studies, which show both mode of exercise as equally beneficial, recommend resistance training as a preferable mode of exercise as it is more accessible to patients with poor cardiorespiratory system⁵³.

Both exercise training modes exert positive effects via a number of different pathways (Figure 3). They by themselves use energy that allows to burn extra fat. Prolonged exercise training also builds muscle mass and increases the basic metabolic rate, allowing for higher overall energy expenditure⁵³. Skeletal muscle mass increases with training, which leads to an increased glucose uptake, over time bypassing insulin resistance⁵². To support this, most exercise training studies show

an increase in peripheral, but not hepatic, insulin sensitivity, which still contributes to improved MASLD outcome⁵². Finally, endurance exercise training has been observed to increase the abundance of SCFA-producing gut bacteria, though the mechanisms are not well-studied⁵⁴.

Additionally, exercise training also has an effect on the immune system and inflammation. Specifically, after an exercise bout, skeletal muscles release IL-6^{55,56}. IL-6 has both pro- and anti-inflammatory functions. When released, it binds to IL-6 receptor (IL-6R), which is present on membranes of only some cell types (hepatocytes, leukocytes, endothelial and epithelial cells)^{55,56}. This complex can dimerize with gp130, introducing an anti-inflammatory cascade. However, IL-6R can also be cleaved from the membrane, and bind IL-6 in plasma, forming a pro-inflammatory soluble IL-6/IL-6R complex^{55,56}. Notably, muscle-released IL-6 only induces the anti-inflammatory cascade via binding to the membrane bound IL-6R^{55,56}. Additionally, exercise increases levels of soluble gp130, which inactivates soluble IL-6/IL-6R, further blocking pro-inflammatory activity of IL-6⁵⁷. Consequently, the immune response is partially suppressed and resources are used for muscle maintenance instead. As most of the cardiometabolic disorders are inflammatory, prolonged exercise training may have positive anti-inflammatory effects⁵⁸.

Overall, exercise is a great life-style intervention for improving cardiometabolic health, addressing both weight loss and general cardiometabolic improvement.




Figure 3. The effects of exercise on MASLD amelioration. Adapted from Razzak et al (2025)⁵⁹. Please see text for the explanation. Green arrows indicate positive effects of the exercise on the organs. Abbreviation: ALT, alanine aminotransferase.

Circadian biology and exercise training

While it is not a surprise that exercise training is generally beneficial, many questions remain on what frequency, mode and timing of exercise training are optimal for fat loss.

Our body is controlled by circadian rhythms, approximately 24 hour-long cycles of hormonal, physical and behavioral changes. The main circadian regulator is the suprachiasmatic nucleus in the brain, which is in charge of daily body activity. Its activity is regulated by *Zeitgebers* (environmental stimuli), primarily via the sunlight⁶⁰. Disruption of circadian activity is a known contributor to the development of obesity and metabolic disease⁶¹, with nightshift workers having an increased risk to develop obesity and T2D^{62,63}.

Circadian activity of the body is even more complicated by the fact that tissues have their own, peripheral, circadian clocks⁶⁴, affected by more different *Zeitgebers*, such as food intake or exercise. These clocks ensure the stable activity of organs, such as the gut, muscle, or liver, by regulating which processes happen when. A diet rich in

fat may disrupt these peripheral clocks, contributing to the disease development⁶⁵. Hence, aligning daily processes, such as exercise training, to the optimal function of the clock has potential for additional exercise benefits⁶⁶. If utilized right, a good choice of exercise training timing could both reap higher benefits from skeletal muscles or the immune system, and help the body re-synchronize peripheral clocks in metabolic diseases⁶⁷. For building muscle through resistance training, most of the research agrees that exercise training during evening is best⁶⁸. However, for aerobic exercise training there is some conflicting evidence. For instance, studies that measured the period of the highest physical activity arrived at opposing conclusions^{69,70}. One study in patients with obesity and T2D reported that early exercise has actually been unfavorable for patients' glycemic levels, while late exercise exerted benefits⁷¹. Another study with T2D patients showed the opposite results, with late exercise training having no benefits while early exercise training decreased blood glucose levels⁷². A number of other studies also show opposing results, as excellently summarized by Martinez-Montoro et al (2023)⁷³, with slightly more evidence towards late exercise training being more beneficial. Notably, no studies investigating the effect of timing of exercise training in context of MASH have been described as yet.

Exercise and gut microbiota

In addition to the benefits that exercise training exerts on the body, it also has a direct effect on the gut microbiota. Professional athletes, especially runners, have a different microbiota composition compared to healthy individuals with a sedentary lifestyle⁷⁴. Prolonged bouts of exercise, such as running a (ultra-) marathon, can have a significant impact on the gut microbiota composition⁷⁵. Importantly, observed changes, such as an increase in the *Firmicutes/Bacteroidetes* ratio, or an increased abundance of SCFA producers, is not just a by-product of exercise training, but an important adaptation⁷⁶. SCFA influx into muscles increases oxidative capacity of muscles and is beneficial for prolonged endurance exercise⁷⁷. Specifically, SCFA producers in the gut have been described to be able to convert lactate, produced by the muscles, into acetate, butyrate and propionate, serving as fuel for both the gut and muscles^{74,78}.

The gut's response to exercise training also differs between lean and obese exercising individuals. Some studies report that leaner individuals have a bigger shift towards SCFA-producing bacterial taxa and also have higher fecal SCFA levels than

obese individuals⁷⁹, though other studies demonstrate a shift towards SCFA producers despite a lack of overall changes in beta-diversity (i.e., a metric of similarities between samples)⁸⁰. Exercise training may also increase the alpha-diversity in exercising obese patients, a general marker of a more stable and diverse microbiota⁸¹, though only some forms of exercise training appear to induce this change⁸². On a taxonomic level, exercise training increases the abundance of *Akkermansia* genus⁸³, implicated in improved cardiometabolic outcomes⁸⁴.

However, exercise training does not only have a positive effect on the gut. Prolonged or vigorous exercise training exerts a tremendous stress on the body⁸⁵. For instance, vigorous exercise training can cause heat shock and hypoxia (from reduced perfusion) in the gut, which may lead to damage of the gut epithelial lining^{86,87} and to suppression of a number of beneficial bacteria⁸⁸. Hence, production of SCFAs that support the integrity of the intestinal lining, is crucial to counteract these changes. Consequently, it is crucial to study the effects of exercise training on gut health and develop sustainable approaches that do not cause harm to the gut and benefit the body.

Finally, the gut and its microbiome, similarly to many other tissues and processes in the human body, are known to oscillate according to circadian rhythms⁸⁹. Aligning the intestinal clock with other processes, for example, training when SCFA-producing bacteria are increased, can be yet another method to optimize exercise performance or exercise benefits.

Dietary fiber as lifestyle intervention treatment

While effective, exercise training also demands for patients to adhere to the intervention program. Another potentially more simple lifestyle change, is a change in diet. A plethora of different diets exist, though most of them are just different modes of calorie restriction that make it more manageable for patients to limit food intake. Nonetheless, a dietary modification that undoubtedly has a positive long-term impact on cardiometabolic health is the increase of fiber intake⁹⁰. Even in healthy individuals, meeting the recommended levels of fiber intake reduces the chance of cardiometabolic events by 20-30%⁹⁰. Fiber intake is also known to improve insulin sensitivity and accelerate fat loss in patients with T2D^{91,92}.

Fiber intake achieves these effects via a number of mechanisms. First, fiber generally improves digestion and food passage time⁹³. Secondly, fiber serves as fuel

for gut bacteria that can convert these complex carbohydrates via fermentation into SCFAs. SCFAs serve as energy for gut epithelial cells, reducing gut permeability^{94,95}, help to reduce appetite⁹⁶, reduce inflammation³⁶ and improve muscle oxidative capacity⁹⁷ (Figure 4). SCFAs act via G protein coupled receptors (GPRs), mainly GPR41, GPR43 and GPR109A. In plasma, SCFAs lead to a decrease in the levels of total cholesterol, LDL-cholesterol and fasting glucose⁹⁰.




Figure 4. Effects of the most common short-chain fatty acids on cardiometabolic health. Adapted from Drevon (2021)⁹⁸. Please see text for the explanation. Arrows indicate positive effect on the function of several cells and organs. Abbreviations: AMPK, AMP-activated protein kinase; GLP-1; glucagon-like peptide-1; GPR, G protein-coupled receptor; PYY, peptide YY; SCFA, short-chain fatty acid.

Incorporation of higher amounts of fiber into the diet also results in a remodeling of gut microbiota composition¹⁴. Specifically, fiber leads to an additional increase of SCFA producers potentially crucial for long-term positive metabolic outcomes⁹⁹.

While the use of fiber itself is known to be beneficial, the question arises of what would happen if fiber is combined with exercise training, which also increases the abundance of SCFA producers.

Fasting as an emerging alternative lifestyle modification

Finally, different modes of fasting, such as intermittent fasting, alternating day fasting or 5:2 diet (i.e., 2 consecutive fasting days a week) have recently become a popular diet mode that allows for easier management of calorie intake. However, while these fasting modes indeed allow to decrease calorie intake by up to ~30% and hence is a successful weight loss strategy, less is known about the impact of fasting on the gut microbiota. Specifically, the longer and harsher the fast (meaning very low calorie intake), the less energy the gut microbiota has access to.

This impact of fasting on the microbiota is only beginning to be studied. Intermittent fasting has been shown to increase microbial richness and in most studies also changes microbial composition¹⁰⁰. However, prolonged extreme fasting (5+ days with more than 90% calorie reduction), despite positive metabolic effects, results in a reduction of bacterial diversity, a negative factor that may hurt colonization resistance and heighten the risk for developing infections¹⁰¹, and in an increase in the mucus-degrading bacteria that may damage epithelial lining¹⁰². Recently, fasting-mimicking diets, containing a low amount of calories, emerged as a new fasting alternative^{103,104}. Individuals on these diets fast for a week per month, mimicking the effects of the fasting, but avoiding the aforementioned negative side effects. This approach may also possibly maintain the desirable microbes in the gut. More research into these fasting diets is warranted to optimize positive effects of the fasting while protecting and improving the gut microbiota and maximize fasting benefits.

Thesis outline

As outlined in **chapter 1**, there is a clear need for further optimization of lifestyle interventions to target MASLD, obesity and related cardiometabolic complications, mainly aimed at maximizing the effect of the intervention benefits, in part by improving the gut microbiota composition. While exercise training is a popular and accessible intervention, there are still many unanswered questions about its influence on organs and their cross-talk in health and disease. Consequently, most studies described in this thesis are devoted to modifying exercise training interventions to improve their cardiometabolic and anti-inflammatory benefits.

In **chapter 2**, we reviewed the existing knowledge on the impact of circadian exercise training on the immune system and inflammation. We summarized the findings on different modes of morning and evening exercise training in healthy adults and discussed the implications of these findings for the use of the exercise training as a therapeutic tool.

Next, in **chapter 3**, we aimed to investigate the impact of early and late active period exercise training on inflammatory changes in the early stages of MASLD. To do that, we used young male APOE*3-Leiden.CETP mice with developing liver steatosis, by being fed a high-fat diet. These mice were subjected to moderate exercise training on a treadmill either one hour after the start of their active period, or one hour before the end of their active period.

To investigate the effects of timed exercise training further, in **chapter 4**, we conducted a similar experiment in older mice that stayed on the high-fat diet longer. That allowed us to investigate the effects of timed exercise training on advanced liver steatosis. Since we found that exercise training in the late active period modified the gut microbiota composition, we also conducted a fecal microbiota transplantation to investigate the causal effect of this late exercise-modulated gut microbiota on MASLD development.

Exercise clearly has a pronounced effect on the gut microbiota composition. In **chapter 5**, we investigated the effect of exercise on the gut further by studying the impact of moderate and vigorous exercise training on the gut state in male C57BL/6J mice. In addition to gut microbiota composition itself, we also aimed to investigate changes in the gut epithelial lining, which can be damaged with intense training.

In most of the aforementioned studies, exercise changed the SCFA production in the gut. As the main source of SCFA is the fermentation of fiber, in **chapter 6**, we aimed to elucidate whether the addition of inulin, a dietary fiber, aids in ameliorating MASLD further, alone or combined with late active period exercise. To study this, we once again used male APOE*3-Leiden.CETP mice with fully developed steatosis.

To further understand the impact of lifestyle interventions on gut microbiome in the context of metabolic health, in **chapter 7**, we investigated the impact of prolonged treatment with repeated fasting, and its longitudinal impact, on the gut microbiota composition and functionality in patients with T2D.

Finally, in **chapter 8**, we discuss the findings in context of the currently available literature, and propose a framework for the future studies, and **chapter 9** summarizes the findings of this thesis.

References

1. Nagi MA, Ahmed H, Rezaq MAA, et al. Economic costs of obesity: a systematic review. *Int J Obesity*. Jan 2024;48(1):33-43. doi:10.1038/s41366-023-01398-y
2. (WHO) WHO. Obesity and Overweight. Accessed January 10, 2025, 2025. <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>
3. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. *J Lipid Res*. Jan 2024;65(1)doi:10.1016/j.jlr.2023.100485
4. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. *Lancet*. Jun 5 2021;397(10290):2212-2224. doi:10.1016/S0140-6736(20)32511-3
5. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. *Cell*. May 13 2021;184(10):2537-2564. doi:10.1016/j.cell.2021.04.015
6. Kokkorakis M, Boutari C, Hill MA, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges. *Metabolism*. May 2024;154doi:10.1016/j.metabol.2024.155835
7. Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. *Adv Nutr*. Mar 2017;8(2):253-265. doi:10.3945/an.116.013730
8. Richtlijndatabase. Richtlijn MASLD MASH: Leefstijlinterventies. Accessed January 10, 2025, 2025. https://richtlijndatabase.nl/richtlijn/richtlijn_masld_mash/leefstijlinterventies.html
9. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. *Int J Obesity*. Aug 2015;39(8):1188-1196. doi:10.1038/ijo.2015.59
10. Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. *Clin Sci*. Feb 2013;124(3-4):231-241. doi:10.1042/Cs20120223
11. MacLean PS, Higgins JA, Giles ED, Sherk VD, Jackman MR. The role for adipose tissue in weight regain after weight loss. *Obes Rev*. Feb 2015;16:45-54. doi:10.1111/obr.12255

12. Strohacker K, McCaffery JM, MacLean PS, Wing RR. Adaptations of leptin, ghrelin or insulin during weight loss as predictors of weight regain: a review of current literature. *Int J Obesity*. Mar 2014;38(3):388-396. doi:10.1038/ijo.2013.118
13. Hinte LC, Castellano-Castillo D, Ghosh A, et al. Adipose tissue retains an epigenetic memory of obesity after weight loss. *Nature*. Nov 18 2024;doi:10.1038/s41586-024-08165-7
14. Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. *Nat Rev Microbiol*. Nov 2023;21(11):719-733. doi:10.1038/s41579-023-00904-3
15. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. *Nature*. Jan 22 2009;457(7228):480-U7. doi:10.1038/nature07540
16. Maestri M, Santopaolo F, Pompili M, Gasbarrini A, Ponziani FR. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies. *Front Nutr*. Feb 16 2023;10doi:10.3389/fnut.2023.1110536
17. Ridaura VK, Faith JJ, Rey FE, et al. Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice. *Science*. Sep 6 2013;341(6150):1079-U49. doi:10.1126/science.1241214
18. Houghton D, Stewart CJ, Day CP, Trenell M. Gut Microbiota and Lifestyle Interventions in NAFLD. *Int J Mol Sci*. Apr 2016;17(4)doi:10.3390/ijms17040447
19. Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. *Int J Mol Sci*. Aug 2020;21(16)doi:10.3390/ijms21165888
20. Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. *Jhepr Rep*. Jun 2021;3(3)doi:10.1016/j.jhepr.2021.100261
21. Day CP, James OFW. Steatohepatitis: A tale of two "hits"? *Gastroenterology*. Apr 1998;114(4):842-845. doi:10.1016/S0016-5085(98)70599-2
22. Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: A tale of "second hit". *World J Gastroentero*. Feb 28 2013;19(8):1158-1165. doi:10.3748/wjg.v19.i8.1158
23. Yoon EL, Jun DW. Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology. *Clin Mol Hepatol*. Apr 2023;29(2):371-373. doi:10.3350/cmh.2023.0086

24. Berg T. Associations rename fatty liver disease to reduce stigma. *Bmj-Brit Med J*. Jul 10 2023;382doi:10.1136/bmj.p1587
25. Marangoni F, Galli C, Ghiselli A, et al. Palm oil and human health. Meeting report of NFI: Nutrition Foundation of Italy symposium. *Int J Food Sci Nutr*. 2017;68(6):643-655. doi:10.1080/09637486.2016.1278431
26. Li YX, Yang PP, Ye JL, Xu QY, Wu JQ, Wang YD. Updated mechanisms of MASLD pathogenesis. *Lipids Health Dis*. Apr 22 2024;23(1)doi:10.1186/s12944-024-02108-x
27. Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. *Metabolism*. Aug 2016;65(8):1049-1061. doi:10.1016/j.metabol.2016.02.014
28. Sumida Y, Niki E, Naito Y, Yoshikawa T. Special issue on "Oxidative stress and redox signaling in the gastrointestinal tract and related organs" for Free Radical Research Involvement of free radicals and oxidative stress in NAFLD/NASH. *Free Radical Res*. Nov 2013;47(11):869-880. doi:10.3109/10715762.2013.837577
29. Yan MY, Cui YM, Xiang Q. Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions. *Theranostics*. 2025;15(5):1715-1740. doi:10.7150/thno.106597
30. Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. *Gut*. Oct 2018;67(10):1881-1891. doi:10.1136/gutjnl-2017-314307
31. Carpino G, Del Ben M, Pastori D, et al. Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. *Hepatology*. Aug 2020;72(2):470-485. doi:10.1002/hep.31056
32. Meijnikman AS, Davids M, Herrema H, et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. *Nat Med*. Oct 2022;28(10):2100-+. doi:10.1038/s41591-022-02016-6
33. Zhao HM, Yang AH, Mao LN, Quan YN, Cui JJ, Sun YY. Association Between Dietary Fiber Intake and Non-alcoholic Fatty Liver Disease in Adults. *Front Nutr*. Nov 19 2020;7doi:10.3389/fnut.2020.593735
34. de Oca APM, Julian MT, Ramos A, Puig-Domingo M, Alonso N. Microbiota, Fiber, and NAFLD: Is There Any Connection? *Nutrients*. Oct 2020;12(10)doi:10.3390/nu12103100
35. Malesza JJ, Malesza M, Walkowiak J, et al. High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review. *Cells-Basel*. Nov 2021;10(11)doi:10.3390/cells10113164

36. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High Fat Diet-Induced Gut Microbiota Exacerbates Inflammation and Obesity in Mice via the TLR4 Signaling Pathway. *Plos One*. Oct 16 2012;7(10)doi:10.1371/journal.pone.0047713
37. Keller MIN, S.; Podlesny, D.; Kim, C. Y.; Robbani, S. M.; Schudoma, C.; Fullam, A.; Richter, J.; Letunic, I.; Akanni, W.; Orakov, A.; Schmidt, T. S.; Marotta, F.; Trebicka, J.; Kuhn, M.; Van Rossum, T.; Bork, P. Refined Enterotyping Reveals Dysbiosis in Global Fecal Metagenomes. *Biorxiv*. August 14, 2024. 2024;doi:10.1101/2024.08.13.607711v2
38. Wiertsema SP, Van Bergenhenegouwen J, Garssen J, Knippels LMJ. The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies. *Nutrients*. Mar 2021;13(3)doi:10.3390/nu13030886
39. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. *Aliment Pharm Ther*. Jan 15 2008;27(2):104-119. doi:10.1111/j.1365-2036.2007.03562.x
40. Moreira APB, Texeira TFS, Ferreira AB, Peluzio MDG, Alfenas RDG. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. *Brit J Nutr*. Sep 14 2012;108(5):801-809. doi:10.1017/S0007114512001213
41. Page MJ, Kell DB, Pretorius E. The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation. *Chronic Stress (Thousand Oaks)*. Jan-Dec 2022;6:24705470221076390. doi:10.1177/24705470221076390
42. Song MY, Chan AT, Sun J. Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. *Gastroenterology*. Jan 2020;158(2):322-340. doi:10.1053/j.gastro.2019.06.048
43. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives. *Hepatology*. Jan 2017;65(1):350-362. doi:10.1002/hep.28709
44. Lai JM, Luo L, Zhou T, Feng XC, Ye JZ, Zhong BH. Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis. *Biomolecules*. Sep 2023;13(9)doi:10.3390/biom13091356
45. Bayoumy AB, Mulder CJJ, Mol JJ, Tushuizen ME. Gut fermentation syndrome: A systematic review of case reports. *United Eur Gastroent*. Apr 2021;9(3):332-342. doi:10.1002/ueg2.12062

46. Meijnikman AS, Nieuwdorp M, Schnabl B. Endogenous ethanol production in health and disease. *Nat Rev Gastro Hepat*. Aug 2024;21(8):556-571. doi:10.1038/s41575-024-00937-w
47. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol*. Oct 2017;67(4):829-846.
48. Ahmed HM, Blaha MJ, Nasir K, Rivera JJ, Blumenthal RS. Effects of Physical Activity on Cardiovascular Disease. *Am J Cardiol*. Jan 15 2012;109(2):288-295. doi:10.1016/j.amjcard.2011.08.042
49. Donnelly JE, Smith B, Jacobsen DJ, et al. The role of exercise for weight loss and maintenance. *Best Pract Res Clin Nutr*. Dec 2004;18(6):1009-1029. doi:10.1016/j.bpg.2004.06.022
50. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology*. Aug 2015;149(2):367-+. doi:10.1053/j.gastro.2015.04.005
51. Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of Aerobic Versus Resistance Exercise Without Caloric Restriction on Abdominal Fat, Intrahepatic Lipid, and Insulin Sensitivity in Obese Adolescent Boys A Randomized, Controlled Trial. *Diabetes*. Nov 2012;61(11):2787-2795. doi:10.2337/db12-0214
52. Mambrini SP, Grillo A, Colosimo S, et al. Diet and physical exercise as key players to tackle MASLD through improvement of insulin resistance and metabolic flexibility. *Front Nutr*. Aug 20 2024;11doi:10.3389/fnut.2024.1426551
53. Hashida R, Kawaguchi T, Bekki M, et al. Aerobic resistance exercise in non-alcoholic fatty liver disease: A systematic review. *J Hepatol*. Jan 2017;66(1):142-152. doi:10.1016/j.jhep.2016.08.023
54. Craven J, Cox AJ, Bellinger P, et al. The influence of exercise training volume alterations on the gut microbiome in highly-trained middle-distance runners. *Eur J Sport Sci*. Aug 3 2022;22(8):1222-1230. doi:10.1080/17461391.2021.1933199
55. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Bba-Mol Cell Res*. May 2011;1813(5):878-888. doi:10.1016/j.bbamcr.2011.01.034
56. Rose-John S. IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6. *Int J Biol Sci*. 2012;8(9):1237-1247. doi:10.7150/ijbs.4989

57. Gray SR, Robinson M, Nimmo MA. Response of plasma IL-6 and its soluble receptors during submaximal exercise to fatigue in sedentary middle-aged men. *Cell Stress Chaperon*. Jun 2008;13(2):247-251. doi:10.1007/s12192-008-0019-3
58. Farzanegi P, Dana A, Ebrahimpour Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. *Eur J Sport Sci*. Aug 9 2019;19(7):994-1003. doi:10.1080/17461391.2019.1571114
59. Razzak IA, Fares A, Stine JG, Trivedi HD. The Role of Exercise in Steatotic Liver Diseases: An Updated Perspective. *Liver Int*. Jan 2025;45(1)doi:10.1111/liv.16220
60. Quante M, Mariani S, Weng J, et al. Zeitgebers and their association with rest-activity patterns. *Chronobiol Int*. Feb 1 2019;36(2):203-213. doi:10.1080/07420528.2018.1527347
61. Saran AR, Dave S, Zarrinpar A. Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease. *Gastroenterology*. May 2020;158(7):1948-+. doi:DOI 10.1053/j.gastro.2020.01.050
62. Sun M, Feng W, Wang F, et al. Meta-analysis on shift work and risks of specific obesity types. *Obes Rev*. Jan 2018;19(1):28-40. doi:10.1111/obr.12621
63. Manoogian ENC, Zadourian A, Lo HC, et al. Feasibility of time-restricted eating and impacts on cardiometabolic health in 24-h shift workers: The Healthy Heroes randomized control trial. *Cell Metab*. Oct 4 2022;34(10):1442-+. doi:10.1016/j.cmet.2022.08.018
64. Manella G, Sabath E, Aviram R, et al. The liver-clock coordinates rhythmicity of peripheral tissues in response to feeding. *Nat Metab*. Jun 2021;3(6):829-+. doi:10.1038/s42255-021-00395-7
65. Lopez DEG, Lashinger LM, Weinstock GM, Bray MS. Circadian rhythms and the gut microbiome synchronize the host's metabolic response to diet. *Cell Metab*. May 4 2021;33(5):873-887. doi:10.1016/j.cmet.2021.03.015
66. Bruns DR, Yusifova M, Marcello NA, Green CJ, Walker WJ, Schmitt EE. The Peripheral Circadian Clock and Exercise: Lessons from Young and Old Mice. *J Circadian Rhythms*. Dec 16 2020;18:7. doi:10.5334/jcr.201
67. Tahara Y, Shibata S. Entrainment of the mouse circadian clock: Effects of stress, exercise, and nutrition. *Free Radical Bio Med*. May 1 2018;119:129-138. doi:10.1016/j.freeradbiomed.2017.12.026
68. K  usmaa M, Schumann M, Sedliak M, et al. Effects of morning versus evening combined strength and endurance training on physical performance,

muscle hypertrophy, and serum hormone concentrations. *Appl Physiol Nutr Me.* Dec 2016;41(12):1285-1294. doi:10.1139/apnm-2016-0271

69. van der Velde JHPM, Boone SC, Winters-van Eekelen E, et al. Timing of physical activity in relation to liver fat content and insulin resistance. *Diabetologia.* Mar 2023;66(3):461-471. doi:10.1007/s00125-022-05813-3

70. Albalak G, Stijntjes M, van Bodegom D, et al. Setting your clock: associations between timing of objective physical activity and cardiovascular disease risk in the general population. *Eur J Prev Cardiol.* Feb 14 2023;30(3):232-240. doi:10.1093/eurjpc/zwac239

71. Savikj M, Gabriel BM, Alm PS, et al. Afternoon exercise is more efficacious than morning exercise at improving blood glucose levels in individuals with type 2 diabetes: a randomised crossover trial. *Diabetologia.* Feb 2019;62(2):233-237. doi:10.1007/s00125-018-4767-z

72. Teo SYM, Kanaley JA, Guelfi KJ, Marston KJ, Fairchild TJ. The Effect of Exercise Timing on Glycemic Control: A Randomized Clinical Trial. *Medicine & Science in Sports & Exercise.* Feb 2020;52(2):323-334. doi:10.1249/Mss.0000000000002139

73. Martínez-Montoro JI, Benítez-Porres J, Tinahones FJ, Ortega-Gómez A, Murri M. Effects of exercise timing on metabolic health. *Obes Rev.* Oct 2023;24(10)doi:10.1111/obr.13599

74. Scheiman J, Lubner JM, Chavkin TA, et al. Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism. *Nat Med.* Jul 2019;25(7):1104-+. doi:10.1038/s41591-019-0485-4

75. Grosicki GJ, Durk RP, Bagley JR. Rapid gut microbiome changes in a world-class ultramarathon runner. *Physiol Rep.* Dec 2019;7(24)doi:10.14814/phy2.14313

76. Durk RP, Castillo E, Márquez-Magaña L, et al. Gut Microbiota Composition Is Related to Cardiorespiratory Fitness in Healthy Young Adults. *Int J Sport Nutr Exe.* May 2019;29(3):249-253. doi:10.1123/ijsnem.2018-0024

77. Hughes RL. A Review of the Role of the Gut Microbiome in Personalized Sports Nutrition. *Front Nutr.* Jan 10 2020;6doi:10.3389/fnut.2019.00191

78. Belenguer A, Holtrop G, Duncan SH, et al. Rates of production and utilization of lactate by microbial communities from the human colon. *Fems Microbiol Ecol.* Jul 2011;77(1):107-119. doi:10.1111/j.1574-6941.2011.01086.x

79. Allen JM, Mailing LJ, Niemi GM, et al. Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans. *Med Sci Sport Exer.* Apr 2018;50(4):747-757. doi:10.1249/Mss.0000000000001495

80. Verheggen RJHM, Konstanti P, Smidt H, Hermus ARMM, Thijssen DHJ, Hopman MTE. Eight-week exercise training in humans with obesity: Marked improvements in insulin sensitivity and modest changes in gut microbiome. *Obesity*. Oct 2021;29(10):1615-1624. doi:10.1002/oby.23252
81. Kern T, Blond MB, Hansen TH, et al. Structured exercise alters the gut microbiota in humans with overweight and obesity-A randomized controlled trial. *Int J Obesity*. Jan 2020;44(1):125-135. doi:10.1038/s41366-019-0440-y
82. Silva JSC, Seguro CS, Naves MM. Gut microbiota and physical exercise in obesity and diabetes- A systematic review. *Nutr Metab Cardiovas*. Apr 2022;32(4):863-877. doi:10.1016/j.numecd.2022.01.023
83. Munukka E, Ahtiainen JP, Puigbó P, et al. Six-Week Endurance Exercise Alters Gut Metagenome That Is not Reflected in Systemic Metabolism in Overweight Women. *Front Microbiol*. Oct 3 2018;9doi:10.3389/fmicb.2018.02323
84. Hasani A, Ebrahimzadeh S, Hemmati F, Khabbaz A, Hasani A, Gholizadeh P. The role of Akkermansia muciniphila in obesity, diabetes and atherosclerosis. *J Med Microbiol*. 2021;70(10)doi:10.1099/jmm.0.001435
85. Costa RJS, Snipe RMJ, Kitic CM, Gibson PR. Systematic review: exercise-induced gastrointestinal syndrome-implications for health and intestinal disease. *Aliment Pharm Ther*. Aug 2017;46(3):246-265. doi:10.1111/apt.14157
86. JanssenDuijghuijsen LM, Mensink M, Lenaerts K, et al. The effect of endurance exercise on intestinal integrity in well-trained healthy men. *Physiol Rep*. Oct 2016;4(20)doi:10.14814/phy2.12994
87. de Oliveira EP, Burini R, Jeukendrup A. Gastrointestinal Complaints During Exercise: Prevalence, Etiology, and Nutritional Recommendations. *Sports Med*. May 2014;44:79-85. doi:10.1007/s40279-014-0153-2
88. Clauss M, Gérard P, Mosca A, Leclerc M. Interplay Between Exercise and Gut Microbiome in the Context of Human Health and Performance. *Front Nutr*. Jun 10 2021;8doi:10.3389/fnut.2021.637010
89. Thaïss CA, Levy M, Korem T, et al. Microbiota Diurnal Rhythmicity Programs Host Transcriptome Oscillations. *Cell*. Dec 1 2016;167(6):1495-1510 e12. doi:10.1016/j.cell.2016.11.003
90. Reynolds AN, Akerman A, Kumar S, Pham HTD, Coffey S, Mann J. Dietary fibre in hypertension and cardiovascular disease management: systematic review and meta-analyses. *Bmc Med*. Apr 22 2022;20(1)doi:10.1186/s12916-022-02328-x
91. Ojo O, Feng QQ, Ojo OO, Wang XH. The Role of Dietary Fibre in Modulating Gut Microbiota Dysbiosis in Patients with Type 2 Diabetes: A

Systematic Review and Meta-Analysis of Randomised Controlled Trials. *Nutrients*. Nov 2020;12(11)doi:10.3390/nu12113239

92. Salamone D, Rivellese AA, Vetrani C. The relationship between gut microbiota, short-chain fatty acids and type 2 diabetes mellitus: the possible role of dietary fibre. *Acta Diabetol*. Sep 2021;58(9):1131-1138. doi:10.1007/s00592-021-01727-5
93. de Vries J, Miller PE, Verbeke K. Effects of cereal fiber on bowel function: A systematic review of intervention trials. *World J Gastroentero*. Aug 7 2015;21(29):8952-8963. doi:10.3748/wjg.v21.i29.8952
94. Usuda H, Okamoto T, Wada K. Leaky Gut: Effect of Dietary Fiber and Fats on Microbiome and Intestinal Barrier. *Int J Mol Sci*. Jul 2021;22(14)doi:10.3390/ijms22147613
95. Kim Y, Hwang SW, Kim S, et al. Dietary cellulose prevents gut inflammation by modulating lipid metabolism and gut microbiota. *Gut Microbes*. 2020;11(4)doi:10.1080/19490976.2020.1730149
96. Li Z, Kooijman S, Yi CX, et al. Butyrate Via the Gut-Brain Neuronal Circuit Reduces Appetite and Activates Brown Adipose Tissue. *Atherosclerosis*. Aug 2017;263:E85-E85. doi:DOI 10.1016/j.atherosclerosis.2017.06.277
97. Frampton J, Murphy KG, Frost G, Chambers ES. Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function. *Nat Metab*. Sep 2020;2(9):840-848. doi:10.1038/s42255-020-0188-7
98. A.; DC. Short-chain fatty acids (SCFAs): Friend or foe? <https://www.vitas.no/articles/short-chain-fatty-acids-scfas-friend-or-foe>
99. Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. *Gut Microbes*. Jan 1 2021;13(1)doi:10.1080/19490976.2021.1897212
100. Paukkonen I, Törrönen EN, Lok J, Schwab U, El-Nezami H. The impact of intermittent fasting on gut microbiota: a systematic review of human studies. *Front Nutr*. Feb 12 2024;11doi:10.3389/fnut.2024.1342787
101. von Schwartzberg RJ, Bisanz JE, Lyalina S, et al. Caloric restriction disrupts the microbiota and colonization resistance. *Nature*. Jul 8 2021;595(7866):272-+. doi:10.1038/s41586-021-03663-4
102. Ducarmon QRG, F.; Giannopoulou, C.; Loumé, A.; Karcher, N.; Larralde, M.; Romano, S.; MacArthur, M. R.; Mitchell, S. J.; Wilhelmi de Toledo, F.; Zeller, G.; Mesnage, R.

<https://www.biorxiv.org/content/10.1101/2024.04.19.590209v1.full#F3>. *bioRxiv*. 2024;doi:<https://doi.org/10.1101/2024.04.19.590209>

103. Mishra A, Mirzaei H, Guidi N, et al. Fasting-mimicking diet prevents high-fat diet effect on cardiometabolic risk and lifespan. *Nat Metab*. Oct 2021;3(10):1342-+. doi:10.1038/s42255-021-00469-6

104. Brandhorst S, Levine ME, Wei M, et al. Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. *Nat Commun*. Feb 20 2024;15(1)doi:10.1038/s41467-024-45260-9